Press releases

Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion trial is to be presented at the 56th ASH Annual Meeting and Exposition in San Francisco, CA. The Phase I objective, to establish the maximum tolerated dose (MTD), has been reached with the MTD determined at 40 mg melflufen in combination with dexamethasone and with no dose-limiting toxicity being observed in the first three dose cohorts (15, 25 and 40 mg)

Stockholm, Sweden August 20, 2013 – Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1)

Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides’ management and Board also participated in the round

STOCKHOLM, SWEDEN - October 21, 2011. Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. He started his career as an analyst with Merrill Lynch in London and moved to consultancy with McKinsey in Stockholm, followed by a period in Gothenburg as CEO and co-founder of Cellectricon AB. For the last six years, Jakob has been Vice President and Venture Partner at Investor Growth Capital in Stockholm

STOCKHOLM, SWEDEN – 1 December 2010 – Oncopeptides AB today announced that preclinical results for J1 will be presented this week-end at the ASH Annual Meeting in Orlando, Florida, USA. The abstract 1838, entitled “Anti-Myeloma Activity Of Enzymatically Activated Melphalan Prodrug J1”, will be presented at the I poster session on Saturday, December 4, 2010, 5:30 PM – -7:30 PM Hall A3/A4 (Orange County Convention Center) Poster Board I-818

STOCKHOLM, April 19, 2010 - Oncopeptides AB, today announced that Alan Hulme was elected Chairman of the Board at the statutory annual meeting. Mr Hulme has over 30 years experience in the life science business and wide experience in many sectors and geographic locations